|
Kenneth J. Pienta is the Donald S. Coffey Professor of Urology at the (Brady Urological Institute ) of the Johns Hopkins University School of Medicine. He is also a Professor in the Departments of Oncology and Pharmacology and Molecular Science and serves as a faculty member in the Cellular and Molecular Medicine Program at the Johns Hopkins School of Medicine and a Professor of (Chemical and Biomolecular Engineering in the Whiting School of Engineering at Johns Hopkins University ). Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He serves as the Director of Research for the Brady Urological Institute. Opened in 1915, the Brady Urological Institute was the only one of its kind in the country. It was the number one Urological Institute in the United States for 21 years in a row from 1991 to 2011.〔(The James Buchanan Brady Urological Institute website )〕 Dr. Pienta graduated from the Johns Hopkins School of Medicine, obtaining the M.D. degree in 1986. After graduation, he completed his internal medicine residency at the University of Chicago and then returned to Hopkins for a medical oncology fellowship from 1988-1991. During medical school and again during fellowship training he was mentored by Dr. Donald S. Coffey, focusing on how cancer cell structure and function were altered in cancer cells. After finishing fellowship, he became an Assistant Professor of Medicine and Molecular Biology at the Wayne State University School of Medicine in 1991. Dr. Pienta was recruited to the University of Michigan in 1994 as an Associate Professor of Medicine and Surgery and was promoted to Professor of Internal Medicine and Urology in 1998.〔(【引用サイトリンク】url=http://www.kenpienta.com )〕 From 1995 to 2012, Dr. Pienta served as the Director of the Prostate Specialized Program of Research Excellence (SPORE) at the University of Michigan.〔(University of Michigan Prostate Cancer Specialized Program of Research Excellence (SPORE) website )〕 Dr. Pienta was the Director of Experimental Therapeutics for the Michigan Center for Translational Pathology from 2008 to 2012.〔(Internal Medicine: Faculty Biography - Kenneth Pienta )〕 He served as the Associate Dean for Clinical and Translational Science and Director of the Michigan Institute for Clinical Research (MICHR) from 2008 to 2011 and as the Associate Vice President for Research, Health Sciences for the University of Michigan from 2011 to 2012.〔(Michigan Institute for Clinical Research Website )〕 Dr. Pienta was on the faculty of the Cellular and Molecular Biology, Computational Medicine and Biology, and Cancer Biology graduate programs and is a scholar of the Taubman Research Institute at the University of Michigan.〔(Taubman Research Institute Website )〕 Dr. Pienta’s research career has focused on defining the tumor microenvironment of prostate cancer metastases to develop new therapies for prostate cancer. He has a peer-reviewed track record in organizing and administering a translational research program that incorporates bench research, agent development, and clinical application. He is the author of more than 360 peer-reviewed articles, and been the principal investigator on numerous local and national clinical trials. Dr. Pienta has championed the concept that multi-disciplinary teams of scientists and clinicians best accomplish translational research. Under his direction, the success of these endeavors led to the receipt of the inaugural 2007 American Association for Cancer Research "Team Science" Award for the discovery of gene fusions in prostate cancer.〔(AACR Team Science Award Recipients ), American Association for Cancer Research Award citation:"In recognition of their landmark discovery of recurrent gene fusions in a majority of prostate cancers, which has profound clinical and biological implications for understanding prostate cancers, and their embodiment of team science through interdisciplinary and inter-institutional collaboration."〕 His accomplishments are reflected by his election to the American Society of Clinical Investigation (2005),〔(ASCI - The American Society for Clinical Investigation )〕 induction into the Society of Scholars of the Johns Hopkins University (2011)〔(Johns Hopkins University Commencement 2011: Society of Scholars, 1969 to Present )〕 and League of Research Excellence of the University of Michigan (2011).〔(The League of Research Excellence )〕 Reflecting his expertise in patient care, he has been consistently included in “America’s Top Doctors” and in “Best Doctors” in America for the last 10 years. Throughout his career, Dr. Pienta has served as a model of the “triple-threat” physician – scientist and has effectively mentored more than 40 students, residents, and fellows to successful careers in medicine and science. In 2009, the American Urological Association named him Distinguished Mentor of the Year and he was the recipient of the Prostate Cancer Foundation Core Values Award.〔(【引用サイトリンク】title=Microsoft Word - AR FINAL FY10.01-03-10.jb.doc )〕 In 2011-2012, Dr. Pienta served as the President of the Society for Clinical and Translational Science.〔(Leadership - Society for Clinical and Translational Science )〕 == Research and discovery == Dr. Pienta has championed the concept that cancer is best understood utilizing the principles of Ecology. Ecologists have studied the population biology of invasive species for decades and have documented their impact on local environments as well as the global ecosystem as a whole. Invasive species start as a native population within a defined community and are then transported by some means to a new environment. In this new environment, the invader either then dies off or enters a period of time during which it establishes itself (lag period). It then begins to spread and have impact on the local environment, disrupting the ecosystem as a whole. This disruption has broad implications for the native species and the broader ecosystem. Biologic traits that result in a robust invasive species include rapid proliferative capacity, adaptation to environmental stress (phenotypic plasticity) and high tolerance to environmental heterogeneity. The life cycle of invasive species is directly analogous to the study of cancer metastasis. Cancer must grow in a primary site, extravasate and survive in the circulation to then intravasate at a target organ (invasive species survival in transport). Cancer cells often lay dormant at their metastatic site for a long period of time (lag period) before proliferating (invasive spread). Proliferation in the new site has an impact on the target organ microenvironment (ecological impact) and eventually the human host (biosphere impact). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Kenneth J. Pienta」の詳細全文を読む スポンサード リンク
|